Mizuho Medy Co.,Ltd. (4595.T)
JPY 1452.0
(-0.07%)
JPY 1452.0
(-0.07%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 5.53 Billion JPY | -52.5% |
| 2022 | 11.22 Billion JPY | 63.76% |
| 2021 | 6.99 Billion JPY | 1027.18% |
| 2020 | 611.1 Million JPY | -52.32% |
| 2019 | 1.33 Billion JPY | -2.34% |
| 2018 | 1.29 Billion JPY | 40.87% |
| 2017 | 929.7 Million JPY | 1.2% |
| 2016 | 592.79 Million JPY | 26.33% |
| 2015 | 426.88 Million JPY | -8.01% |
| 2014 | 515.16 Million JPY | 271.14% |
| 2013 | 213 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 647 Million JPY | -54.68% |
| 2024 Q1 | 1.3 Billion JPY | -3.5% |
| 2023 Q4 | 1.41 Billion JPY | -24.98% |
| 2023 Q2 | 875.75 Million JPY | -14.78% |
| 2023 Q3 | 1.88 Billion JPY | 115.34% |
| 2023 FY | - JPY | -52.5% |
| 2023 Q1 | 1.02 Billion JPY | -56.72% |
| 2022 Q2 | 1.83 Billion JPY | -33.35% |
| 2022 Q3 | 4.11 Billion JPY | 124.67% |
| 2022 Q4 | 2.37 Billion JPY | -42.3% |
| 2022 FY | - JPY | 63.76% |
| 2022 Q1 | 2.74 Billion JPY | 166.94% |
| 2021 Q4 | 1.02 Billion JPY | -59.5% |
| 2021 Q3 | 2.54 Billion JPY | 13.09% |
| 2021 Q2 | 2.24 Billion JPY | 155.06% |
| 2021 FY | - JPY | 1027.18% |
| 2021 Q1 | 881.42 Million JPY | 34.42% |
| 2020 Q4 | 655.7 Million JPY | 696.81% |
| 2020 Q3 | -109.86 Million JPY | 13.39% |
| 2020 Q2 | -126.85 Million JPY | -7271.18% |
| 2020 Q1 | -1.72 Million JPY | -100.27% |
| 2020 FY | - JPY | -52.32% |
| 2019 Q2 | 53.74 Million JPY | -85.95% |
| 2019 FY | - JPY | -2.34% |
| 2019 Q4 | 640.38 Million JPY | 566.72% |
| 2019 Q3 | 96.05 Million JPY | 78.71% |
| 2019 Q1 | 382.48 Million JPY | -28.44% |
| 2018 FY | - JPY | 40.87% |
| 2018 Q3 | 97.8 Million JPY | 252.92% |
| 2018 Q1 | 552.88 Million JPY | 2.62% |
| 2018 Q2 | 27.71 Million JPY | -94.99% |
| 2018 Q4 | 534.52 Million JPY | 446.52% |
| 2017 Q3 | 12.42 Million JPY | -2.75% |
| 2017 FY | - JPY | 1.2% |
| 2017 Q1 | 288.62 Million JPY | -38.21% |
| 2017 Q4 | 538.76 Million JPY | 4235.44% |
| 2017 Q2 | 12.77 Million JPY | -95.57% |
| 2016 Q3 | -82.51 Million JPY | -74.15% |
| 2016 Q4 | 467.11 Million JPY | 666.1% |
| 2016 Q1 | 190.52 Million JPY | -34.58% |
| 2016 FY | - JPY | 26.33% |
| 2016 Q2 | -47.38 Million JPY | -124.87% |
| 2015 FY | - JPY | -8.01% |
| 2015 Q4 | 291.23 Million JPY | 0.0% |
| 2014 FY | - JPY | 271.14% |
| 2013 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 6.02 Billion JPY | 8.05% |
| Takeda Pharmaceutical Company Limited | 874.6 Billion JPY | 99.367% |
| Sumitomo Pharma Co., Ltd. | -281.07 Billion JPY | 101.97% |
| Shionogi & Co., Ltd. | 186.7 Billion JPY | 97.035% |
| Wakamoto Pharmaceutical Co.,Ltd. | 570.97 Million JPY | -869.625% |
| Nippon Shinyaku Co., Ltd. | 36.29 Billion JPY | 84.744% |
| Kaken Pharmaceutical Co., Ltd. | 12.26 Billion JPY | 54.868% |
| Eisai Co., Ltd. | 103.1 Billion JPY | 94.63% |
| Morishita Jintan Co., Ltd. | 1.29 Billion JPY | -328.174% |
| Hisamitsu Pharmaceutical Co., Inc. | 18.34 Billion JPY | 69.813% |
| Mochida Pharmaceutical Co., Ltd. | 8.97 Billion JPY | 38.301% |
| Fuso Pharmaceutical Industries,Ltd. | 3.67 Billion JPY | -50.853% |
| Nippon Chemiphar Co., Ltd. | 1.4 Billion JPY | -294.604% |
| Tsumura & Co. | 30.77 Billion JPY | 82.009% |
| Kissei Pharmaceutical Co., Ltd. | 18.72 Billion JPY | 70.426% |
| Torii Pharmaceutical Co., Ltd. | 5.27 Billion JPY | -5.033% |
| Towa Pharmaceutical Co., Ltd. | 35.53 Billion JPY | 84.421% |
| Fuji Pharma Co., Ltd. | 6.88 Billion JPY | 19.554% |
| Zeria Pharmaceutical Co., Ltd. | 17.52 Billion JPY | 68.403% |
| KYORIN Holdings, Inc. | 10.29 Billion JPY | 46.229% |
| Taiko Pharmaceutical Co.,Ltd. | -3.75 Billion JPY | 247.634% |
| Daito Pharmaceutical Co.,Ltd. | 7.55 Billion JPY | 26.701% |
| SymBio Pharmaceuticals Limited | -714 Million JPY | 875.391% |
| MedRx Co., Ltd | -884.51 Million JPY | 725.912% |
| Solasia Pharma K.K. | -635 Million JPY | 971.857% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | 333.213% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 9.16 Billion JPY | 39.58% |
| Sawai Group Holdings Co., Ltd. | 36.87 Billion JPY | 84.986% |
| Cyfuse Biomedical K.K. | -538.28 Million JPY | 1128.498% |
| Toho Holdings Co., Ltd. | 25.84 Billion JPY | 78.579% |
| Koa Shoji Holdings Co.,Ltd. | 5.1 Billion JPY | -8.52% |